Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Science translational medicine·2026
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

Inertial sensing of water content in tumor spheroids.

Science advances·2026
Same author

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Blood advances·2026

Related Experiment Video

Updated: Jun 28, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K

Leukemia circulation kinetics revealed through blood exchange method.

Alex B Miller1,2, Felicia H Rodriguez2,3, Adam Langenbucher2,4

  • 1Harvard-MIT Department of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Boston, MA, USA.

Communications Biology
|April 20, 2024
PubMed
Summary
This summary is machine-generated.

Circulating leukemia cells (CLCs) persist in blood much longer than tumor cells. Leukemia presence and treatment status significantly impact CLC clearance rates, revealing dynamic disease processes.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Related Experiment Videos

Last Updated: Jun 28, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunology

Background:

  • Leukemia and bone marrow microenvironments are dynamic.
  • Circulation kinetics and clearance of leukemia cells are poorly understood.
  • Understanding these dynamics is crucial for disease progression and therapeutic response.

Purpose of the Study:

  • To understand circulating leukemia cell (CLC) dynamics during disease progression and treatment.
  • To investigate factors influencing CLC clearance from blood.
  • To establish a method for quantifying microenvironmental impacts on CLC kinetics.

Main Methods:

  • Utilized a blood exchange method in mouse models of acute leukemia.
  • Quantified circulation times of CLCs.
  • Assessed the impact of leukemia presence in the marrow on CLC clearance.
  • Investigated CLC clearance in relapsed acute myeloid leukemia (AML) models.
  • Evaluated the role of E-selectin in CLC clearance.

Main Results:

  • CLCs circulate 1-2 orders of magnitude longer than circulating tumor cells from solid tumors.
  • Leukemia in the bone marrow can impede CLC clearance in acute lymphocytic leukemia (ALL) models.
  • CLCs in relapsed AML models demonstrate faster clearance than untreated counterparts.
  • E-selectin was identified as a factor influencing CLC clearance.

Conclusions:

  • CLC clearance rates are variable and depend on tumor and treatment status.
  • The study provides a strategy to identify factors governing circulating cell kinetics.
  • Findings offer insights into leukemia cell behavior in circulation and potential therapeutic targets.